Veninga, Vivien

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 1,417

Tumor organoids: Opportunities and challenges to guide precision medicine

Veninga, V., & Voest, E. E. (2021) · Cancer Cell

Cancer Cells and Metastasis3D Printing in Biomedical Research

Cited by 339

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

de Vries, N. L., van de Haar, J., Veninga, V., Chalabi, M., Ijsselsteijn, M. E., van der Ploeg, M., van den Bulk, J., Ruano, D., van den Berg, J. G., Haanen, J. B., et al. (2023) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 311